As bstract. We evaluated the effects of the diterpene compound forskolin in human myocardial adenylate cyclase preparations, isolated trabeculae and papillary muscles derived from failing human hearts, and acutely instrumented dogs. Forskolin was a potent, powerful activator of human myocardial adenylate cyclase and produced maximal effects that were 4.82 (normally functioning left ventricle) and 6.13 (failing left ventricle) fold greater than isoproterenol. In contrast to isoproterenol, forskolin retained full activity in membrane preparations derived from failing hearts. In cyclase preparations, forskolin demonstrated unique substrate and Mg2+ kinetic properties that could be distinguished from hormone receptor-coupled agonists or fluoride ion. The adenylate cyclase stimulatory effect of forskolin was synergistic with isoproterenol, apparently due to the location of forskolin activation being beyond the level of hormone receptor-agonist in the receptor-cyclase complex. Forskolin was a potent positive inotrope in failing human myocardium, producing a stimulation ofcontraction that was similar to isoproterenol. Finally, in open chest dogs forskolin was a positive inotropic agent that reduced preload and afterload. We conclude that forskolin belongs to a class of agents that may have therapeutic potential in the treatment of congestive heart failure.
nylate cyclase (1) . In broken cell preparations, this unique compound may directly stimulate the catalytic moiety (C)' of adenylate cyclase without interacting with N, the guanyl nucleotide regulatory subunit of cyclase (3) .
Compounds that stimulate cyclic AMP (cAMP) production increase the contractile state of the heart (4, 5) . In the human heart the most potent pharmacologic agents in this regard are catecholamines that possess f3-adrenergic agonist activity (6) , and both intravenous (7) (8) (9) (10) (11) and orally effective (12, 13) f3-agonists have been used in the treatment of heart failure.
Despite their potency and initial efficacy, fl-adrenergic agonists have one major pharmacologic disadvantage that limits their long-term use. Continuous exposure to catecholamines renders the myocardium subsensitive to j3-adrenergic stimuli (12, 14) by reducing P-receptor density (6, (14) (15) (16) (17) (18) and/or receptor-cyclase coupling (15) (16) (17) (18) . Both of these subsensitivity phenomena are apparently regulated through N, as mutant cells that do not possess N do not exhibit subsensitivity phenomena (19, 20) . It follows that pharmacologic agents that act primarily on C should not demonstrate catecholamine-type subsensitivity phenomena. These agents should also be positive inotropic agents, through activation of myocardial adenylate cyclase (4, 5) . Forskolin does appear to possess positive inotropic activity, on the basis of previous work in isolated guinea pig left atrium (1, 21) .
In this investigation we give the first description ofthe effects offorskolin in tissue derived from failing or normally functioning human heart, and the first detailed analysis of the pharmacologic effects of forskolin on myocardial adenylate cyclase. In the human heart forskolin exhibits positive inotropic characteristics similar to isoproterenol. However, unlike symp- toms, and all were vigorous, young (average age 30 yr) males before suffering fatal head injury (n = 5) or idiopathic cerebral edema (n = 1). Five of the six subjects were considered suitable cardiac transplant donors before the detection of factors excluding the graft (tricuspid endocarditis in one, atrial laceration in one) or late exclusion of wouldbe recipients for acute medical complications (n = 3). Two hearts were procured off-site (22) , and four on-site. Additional normally functioning left ventricular myocardium was obtained from two heart-lung transplant recipients who were The effect of forskolin on fl-adrenergic receptor density, antagonist affinity, and agonist affinity was determined in freshly prepared guinea pig myocardial membranes prepared from whole right and left ventricular preparations derived from 700-900-g male Hartley albino guinea pigs. Membranes were prepared as described in "Method A" of a previous communication (22 nmol/kg per min, while forskolin was dissolved in propylene glycol and infused at 1-100 nmol/kg/min. This amount of propylene glycol had no effect on hemodynamics.
Statistical analysis of differences between two means was by the unpaired or paired t test, with a P < 0.05 in the two-tailed distribution considered to be statistically significant. Also, the increase in MgATP Vmax produced by forskolin was accompanied by a marked increase in the Km. Forskolin and isoproterenol both lowered the Mg2" Ka to a similar extent, but unlike isoproterenol, forskolin also produced a substantial increase in Mg2' Vmax.
Results

Effects
The effects ofguanine nucleotides on isoproterenol, fluoride ion and forskolin stimulation of adenylate cyclase are given in Fig. 4 . In the absence of guanine nucleotides isoproterenol produced very little cyclase activation. In contrast, guanine nucleotides were not required for forskolin stimulation of cyclase, as the forskolin response was not potentiated by either guanosine triphosphate (GTP) or nonhydrolyzable GTP analogue (Gpp(NH)p). In fact, Gpp(NH)p at lo-5 M produced a small amount of noncompetitive inhibition of forskolin activity. Results identical to those in Fig. 4 forskolin, and fluoride ion stimulation of adenylate cyclase in membranes derived from these hearts. Isoproterenol stimulation of cyclase was diminished in membranes derived from failing hearts, in agreement with the decreased (3-receptor density. In contrast, cyclase stimulation by l0-' M forskolin or 10 mM fluoride was not different in the two groups. Synergism ofisoproterenol andforskolin. Since in membrane preparations forskolin appears to directly stimulate C, it would be predicted that receptor-coupled stimulation of cyclase and forskolin effects would be synergistic. This is in fact the case, as shown in Fig. 5 , which shows that forskolin plus isoproterenol has greater-than-additive effects in both human and guinea pig myocardial membranes. The human preparation shown in Fig.   5 was derived from a severely failing heart with a (3-receptor density that was 31% of normal; the addition of forskolin converted the attenuated isoproterenol response to a more normal appearing dose-response curve. In the experiment shown in Fig.  5 , forskolin increased the isoproterenol maximum net stimulation by 2.6-fold and decreased the activation constant (Ka.,d) by 2.5-fold. Additionally, forskolin and histamine also produced synergistic stimulation in guinea pig preparations (data not shown).
Information relative to the synergistic properties offorskolin and isoproterenol was sought in an examination of the effects of each drug alone or the combination on substrate and Mg2' kinetics. In the preparation derived from failing human heart shown in Fig. 5 , forskolin and isoproterenol in combination increased MgATP Vmax to a greater degree than the sum of each agent's individual effects (no agonist, MgATP Vmax = 7.22 pmol Table III , where it can be seen that the effects of forskolin and isoproterenol on MgATP Vmax are greater than additive.
Effect offorskolin on A-receptor density and agonist affinity.
As forskolin has been reported to promote formation of the high affinity agonist binding state in whole cell preparations (30), we thought it important to consider whether forskolin produced increased coupling or an increase in f3-adrenergic receptor density as a potential explanation for the synergistic interaction with isoproterenol. Isoproterenol-ICYP competition curves in the presence and absence of 10 AM forskolin or 100 AM Gpp(NH)p were measured in four guinea pig and one human heart. A representative experiment in guinea pig myocardial membranes is shown in Fig. 6 . The addition of 10 ,M forskolin did not consistently alter the isoproterenol competition curve in any experiment, whereas curves were right-shifted and steepened by the addition ofGpp(NH)p (Fig. 6) . Although no analysis of the relative percent of receptor in a high affinity vs. low affinity states was performed, there was no apparent effect of forskolin on isoproterenol competition in either high or low agonist affinity ranges. In the human heart experiment forskolin had no effect on isoproterenol-ICYP binding.
In Fig. 7 , the inotropic response to forskolin displayed a slower onset, with a mean time to peak effect of 971 s compared with 103 s for isoproterenol (Table IV) . Secondly, whereas the effect of isoproterenol was relatively shortlived (peak effect lasting < 2 min), the response to forskolin was sustained for at least 45 min (Table V) . Third, the response to forskolin could be elicited 30-60 min after an initial dose of isoproterenol whereas myocardial preparations yielded little or no response to isoproterenol challenge 30 min after giving forskolin (Table V) . Full dose-response curves to isoproterenol and forskolin were performed in isolated right ventricular papillary muscles and trabeculae from three subjects, and the mean values are shown in Fig. 8 . As shown in Fig. 8 , forskolin was less potent than isoproterenol on a molar basis, with a 14.6-fold difference in the median effective doses (ED50's).
Maximal responses to forskolin and isoproterenol are given in Table IV (Table V) . Mean additivity data for forskolin addition to isoproterenol are given in Table IV (Fig. 9 A) , cardiac output (Fig. 9 B) and dP/dt (Fig. 9 C) , and dose-related decreases in mean arterial pressure (Fig. 10 A) , peripheral resistance ( Fig. 10 B) , and left atrial pressure (Fig. 10 C) . As for isolated muscle responses, forskolin proved less potent than isoproterenol on a molar basis, by 7.5-(blood pressure) to 63-(cardiac output) fold. With the exception ofcardiac output and left atrial pressure, maximal effects of forskolin were equivalent to those of isoproterenol. The relatively lesser stimulation of cardiac output by forskolin may have been due to a reduction of left ventricular filling pressure by forskolin, as forskolin reduced left atrial pressure and isoproterenol did not (Fig. 10 C) .
Discussion
We evaluated the pharmacology and inotropic potential of forskolin, a diterpene derivative of Coleus forskohlii (1, 21) . Forskolin proved to be a potent activator of human myocardial adenylate cyclase, and produced stimulation over a similar range as did isoproterenol. The degree of maximal activation of adenylate cyclase was an impressive 26-fold greater than basal activity, and 4.8-6.1-fold greater than maximal isoproterenol stimulation.
The mechanism by which forskolin activates human myocardial adenylate cyclase could be distinguished from effects of isoproterenol and fluoride ion (F-). Forskolin's action was beyond the f3-adrenergic receptor, in agreement with a previous investigation in rat myocardial membrane preparations (1) . In contrast to isoproterenol, forskolin did not require guanine nucleotides for activation and was not blocked by propranolol, in agreement with previous studies (1, 3, 2 1) . The Gpp(NH)p is consistent with previous work that describes an inhibitory role for Gpp(NH)p regulation of adenylate cyclase activity (31) . Our data are therefore consistent with a primary effect of forskolin on C, the catalytic subunit of adenylate cyclase. However, since we did not perform extensive pharmacologic or biochemical analyses of potential forskolin-N site interactions, our data do not exclude an additional mechanism of action involving effects on N, as has been described in intact cells (30) .
The effect of forskolin on substrate and Mg2+ kinetics differed from isoproterenol and F-in several respects. Unlike isoproterenol (32), the increase in substrate Vmax produced by forskolin was accompanied by a substantial increase in MgATP Km. This suggests that forskolin increases the number ofsubstrate binding sites and also induces a conformational change in these sites.
Unlike F-(32), forskolin decreases the Mg2" K., in a manner similar to isoproterenol.
Stimulation of adenylate cyclase by forskolin was not decreased in membranes prepared from severely failing human left ventricle. In contrast, stimulation of cyclase by isoproterenol in these membranes was attenuated, secondary to the decreased a-receptor density. F-stimulation, like forskolin, was not different in failing vs. normally functioning myocardium. These data indicate that the catalytic subunit of adenylate cyclase is not affected by end-stage heart failure, and that full enzymatic stimulation may be achieved by agents that act primarily on this subunit.
When forskolin and receptor-coupled agonist stimulation was used in combination, supra-additive or synergistic effects were observed. This would be predicted from the known loci of these agents' sites of action, as in the effector pathway "C," the catalytic moiety of cyclase is in series and distal to "R," the agonist receptor. Stimulation at R can therefore be multiplied by stimulative effects occurring at C. In contrast, in human or guinea pig myocardial membranes, agents that act by parallel pathways, such as two receptor-coupled agonists, produce less than additive stimulation when added in combination (Lemmers, M., and M. Bristow, unpublished observations). The "in series" positioning of R and C in the effector pathway apparently accounted for the observed synergism, as forskolin did not alter the affinity of the :-receptor for isoproterenol, as has been reported in whole cell preparations (30) , and forskolin did not affect receptor density. In membranes derived from failing human hearts, the end result of this fl-agonist-forskolin synergism was to normalize the appearance of the isoproterenol dose-re- 219 Forskolin and the Human Heart .1r.., z.
., 103±15 (7) 971±418 (7) Change in time to peak tension (%) -29.2±1.2 (7) -32.0±1.3 (7) Maximum net increase in tension (mg) 520±105 (9) 530±57 (9) 936±108t (9) ED50 (nA) 23±12 (3) 350±210* (3) Values are given±SEM, with n in parentheses * P < 0.05 vs. isoproterenol. (dyn-s-cm-5) X 10-3; C, 8±4 and 8±4 mmHg.
when forskolin is used in combination with hormone agonists might make forskolin an ideal agent to be used in combination with a catecholamine.
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Forskolin and the Human Heart   14   10   2 Finally, although the consensus ofopinion favors a regulatory role for cAMP in modulating myocardial contractility (4, 5) , recent data have raised questions as to whether adenylate cyclase stimulation mediates the positive inotropic effects of catecholamines in human cardiac tissue (34) . Our results of forskolin activation of human myocardial adenylate cyclase and stimulation of contractility therefore serve to support the hypothesis that cAMP is the second messenger for positively inotropic ,3-agonists.
Obviously, as a nonspecific activator of adenylate cyclase, forskolin may prove to be too toxic to be used clinically. However, it does appear to have many pharmacologically and hemodynamically ideal properties, and therefore may prove useful as a prototype for the development of similar agents that would have a more selective effect on myocardial adenylate cyclase. The results of this study suggest that some degree of myocardial selectivity could be obtained by combination with a p31-agonist, and on theoretical grounds selectivity could also be achieved by combining forskolin with a myocardial-specific phosphodiesterase inhibitor. The positive chronotropic effects of the drug observed in open-chest, anesthetized dogs may prove to be limiting, but its chronotropic effects may not be as marked in subjects with heart failure and elevated peripheral resistance and left atrial pressure. In fact, a previous study in isolated guinea pig heart suggested a preferential effect on force development compared with heart rate (21) .
In summary, forskolin is a potent, powerful activator of human myocardial adenylate cyclase. Its locus of effect is beyond the level of hormone receptors and in series with receptor-coupled stimulation, presumably through a direct action on the catalytic subunit of adenylate cyclase. This positioning of forskolin's effect imparts synergism to the combination of hormone and forskolin, and may mean that physiologic effects of forskolin are devoid of subsensitivity. Forskolin is a potent positive inotropic agent in isolated tissue derived from failing human hearts, and its hemodynamic effects in intact dogs suggest that it or other members of this unique class of compounds may be potentially useful in the treatment of congestive heart failure.
